Prebiotic Constipation Meta-analysis: What the Evidence Says
Prebiotic Constipation Meta-analysis has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mi
Quick Answer
Prebiotic Constipation Meta analysis has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public health sources, so conclusions should be framed as evidence aware guidance rather than medical advice.
Key Takeaways
- 01This page is generated only from sources stored in the Migaku evidence knowledge base.
- 02Current evidence mix: 1 preclinical study.
- 03Claims should be interpreted with the source type, study design, population, and publication date in mind.
- 04This article is educational and does not replace care from a qualified clinician.
Prebiotic Constipation Meta-analysis: What the Evidence Says
Quick Answer
Prebiotic Constipation Meta-analysis has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.
Key Takeaways
- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.
Evidence Map
| Source | Evidence type | Level | Date | Identifier |
|---|---|---|---|---|
| Research progress and controversies in the treatment of functional constipation-related depression with probiotics and prebiotics: a narrative review | preclinical study | 4 | 2026-02-13 | 10.3389/fphar.2026.1735614 |
What The Sources Report
- Gut microbiota dysbiosis is recognized as a common key link: patients with both constipation and depression often exhibit reduced microbial diversity, decreased short-chain fatty acids (SCFAs), lower abundance of probiotic genera (e.g., Bifidobacterium,), and heightened inflammation (;;;;;;;). [Dai Qiuhua (2026); evidence level 4]
- Despite generally high safety profiles, existing clinical evidence remains controversial due to significant heterogeneity and uncertain efficacy, and the underlying mechanisms remain unclear (;;;). [Dai Qiuhua (2026); evidence level 4]
How To Read This Evidence
Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.
Practical Interpretation
For prebiotic constipation meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.
Limits Of This First Pass
This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.
References
- Dai Qiuhua (2026). Research progress and controversies in the treatment of functional constipation-related depression with probiotics and prebiotics: a narrative review. DOI: 10.3389/fphar.2026.1735614. PMCID: PMC12946840. PMID: 41769687. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12946840/
Safety Note
Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.
FAQ
Frequently Asked Questions
Medically reviewed
Last reviewed May 27, 2026 by Migaku Evidence Review
